EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

Niclosamide prodrug enhances oral bioavailability and efficacy against hepatocellular carcinoma by targeting vasorin‐TGFβ signalling

Mingdian Tan, Wei Ye, Yi Liu, Xiaowu Chen, Lakshmi Huttad, Mei-Sze Chua, Samuel So

British Journal of Pharmacology · 2025-11 · 182 (22) · 5517-5535

DOI: 10.1111/bph.70126 ↗

At a glance

Journal article in British Journal of Pharmacology, published online on 2025-07-22. Written by Mingdian Tan and 6 co-authors. Institution: Department of Surgery, School of Medicine, Asian Liver Center, Stanford University, Palo Alto, CA, USA. Major MEDLINE topics: Carcinoma, Hepatocellular, Liver Neoplasms, Prodrugs, Niclosamide. Cited 7 times so far (Crossref); 56 references. The full text is freely available (open access, CC BY 4.0). Funded by: Translational Research and Applied Medicine, School of Medicine, Stanford University, CJ Huang Foundation, Mavis and CH Fong.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background and Purpose Hepatocellular carcinoma (HCC), the third leading cause of cancer‐related deaths worldwide, has limited treatment options and high mortality rate. We previously used a bioinformatics approach to identify niclosamide (NIC) as a promising repurposed drug candidate for HCC. However, its poor water solubility and low bioavailability limit its clinical efficacy. It's mechanisms of action are not yet fully understood. Experimental Approach We designed a water‐soluble NIC prodrug (NIC‐PS) and evaluated its efficacy (as single agent, or in combination with sorafenib or anti‐PD‐L1) and mechanisms using cell‐based functional assays and HCC patient‐derived xenograft (PDX) mouse models. We established vasorin knockout mouse tumour models and used RNA‐seq to investigate the role of vasorin in mediating NIC‐PS function. Western blotting and real‐time PCR were used to validate the RNA‐seq data and the biological effects of NIC‐PS and vasorin. Key Results NIC‐PS exhibited a 10‐fold increase in oral bioavailability and > 75% reduction in tumour volume in HCC PDX models. NIC binds to vasorin, and both NIC and NIC‐PS suppressed vasorin expression, leading to suppression of TGFβ signalling and SMAD2/3 phosphorylation. NIC‐PS enhanced the sensitivity of HCC cells and PDX to treatment with sorafenib or anti‐PD‐L1. Vasorin knockout results in similar effects as NIC‐PS, suggesting that it partially mediates the actions of NIC‐PS. Conclusion and Implications NIC‐PS demonstrated improved bioavailability and antitumour efficacy compared with NIC and a potential for combination therapy with standard of care agents in HCC treatment. We also revealed its novel mechanism of action in targeting vasorin.

Subjects

MeSH terms (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsProdrugsNiclosamideTransforming Growth Factor betaAntineoplastic AgentsAnimalsHumansBiological AvailabilityMiceSignal TransductionAdministration, OralMice, KnockoutMaleXenograft Model Antitumor AssaysCell Line, TumorMice, Nude

Author keywords

PD‐L1hepatocellular carcinomaniclosamideprodrugvasorinβ

Substances

ProdrugsNiclosamideTransforming Growth Factor betaAntineoplastic Agents

Authors and institutions

  • Department of Surgery, School of Medicine, Asian Liver Center, Stanford University, Palo Alto, CA, USA.
  • Guangzhou JOYO Pharmaceutical Co. Ltd, Guangzhou, China.
  • Shanghai CureGene Pharmaceutical Co, Ltd., Shanghai, China.

Funding

  • Translational Research and Applied Medicine, School of Medicine, Stanford University
  • CJ Huang Foundation, Mavis and CH Fong

Cite

APA

Tan, M., Ye, W., Liu, Y., Chen, X., Huttad, L., Chua, M. S., & So, S. (2025). Niclosamide prodrug enhances oral bioavailability and efficacy against hepatocellular carcinoma by targeting vasorin‐TGFβ signalling. British Journal of Pharmacology, 182(22), 5517-5535. https://doi.org/10.1111/bph.70126

Vancouver

Tan M, Ye W, Liu Y, Chen X, Huttad L, Chua MS, et al. Niclosamide prodrug enhances oral bioavailability and efficacy against hepatocellular carcinoma by targeting vasorin‐TGFβ signalling. British Journal of Pharmacology. 2025;182(22):5517-5535. doi:10.1111/bph.70126

BibTeX
@article{Tan2025,
  author = {Tan, Mingdian and Ye, Wei and Liu, Yi and Chen, Xiaowu and Huttad, Lakshmi and Chua, Mei-Sze and So, Samuel},
  title = {Niclosamide prodrug enhances oral bioavailability and efficacy against hepatocellular carcinoma by targeting vasorin‐TGFβ signalling},
  journal = {British Journal of Pharmacology},
  year = {2025},
  volume = {182},
  number = {22},
  pages = {5517--5535},
  doi = {10.1111/bph.70126}
}
Start for free →